RNA Vaccines for Allergy Prophylaxis
The ultimate goal of our research is the prevention of sensitization against allergens in early childhood. To achieve this challenging goal, the vaccines to be used need to be completely free of safety concerns.
4th generation allergy vaccinations based on RNA vaccines are Biomay's focus for efficient allergy prophylaxis. RNA vaccines are not regulated as gene therapy and do not pose the risk of persistent allergen expression due to the impossibility of genomic integration.
RNA vaccines provoke a transient expression of allergens after uptake into allergen-presenting cells. Allergen fragment peptides are presented on MHC and may induce the production of protective IgGs as well as priming long lasting Th1 reactions.
Biomay succeeded in showing the pre-clinical proof of concept of this next generation prophylactic vaccine. Patents held by Biomay protect this technology that offers a generic platform for all allergens with known sequences.
Flyer RNA-Vaccines, PDF ~76 KB